Resources
12 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders
Posted 12/23/2020 (updated 4/4/2024)
This toolkit is designed primarily for substance use and child welfare practitioners, as well as other service providers and health system planners who offer services to, or design services with, pregnant women and new mothers who use substances. Much is changing in the substance use and child welfare fields to bring forth approaches that are culturally safe, trauma informed, harm reduction-oriented and participant-driven. This toolkit highlights these advances and invites people working in both systems to think about how we can continue to improve our work, in partnership with the women who use these services.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/7/2020 (updated 3/29/2024)
This toolkit contains clinical materials targeting treatment of substance use disorder in the acute care setting.
Posted 9/1/2020 (updated 3/29/2024)
To raise awareness of increasing overdose events and deaths related to cocaine and other stimulant use, and to provide guidance to health care providers on clinically managing and preventing harm from cocaine and stimulant use disorders.
Posted 1/24/2020 (updated 3/28/2024)
Get Naloxone Now is an online resource to train people to respond effectively to an opioid overdose emergency.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Treasury Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 7/27/2020 (updated 3/28/2024)
The American Medical Association’s Opioid Task Force report shows a dramatic increase in fatalities involving illicit opioids, stimulants (e.g. methamphetamine), heroin and cocaine and a similarly dramatic drop in the use of prescription opioids.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.